Drug Enforcement Administration (DEA), Department of Justice.
The Drug Enforcement Administration (DEA) is finalizing an Interim Rule designating six pharmaceutical preparations as exempt anabolic steroid products under the Controlled Substances Act. This action is part of the ongoing implementation of the Anabolic Steroids Control Act of 1990.
Effective Date: This final rule is effective April 16, 2008.Start Further Info
FOR FURTHER INFORMATION CONTACT:
Christine A. Sannerud, PhD, Chief, Drug and Chemical Evaluation Section, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Telephone: (202) 307-7183.End Further Info End Preamble Start Supplemental Information
The Anabolic Steroids Control Act (ASCA) of 1990 (Title XIX of Pub. L. 101-647) placed anabolic steroids into schedule III of the Controlled Substances Act (CSA). Section 1903 of the ASCA provides that the Attorney General may exempt products which contain anabolic steroids from all or any part of the CSA (21 U.S.C. 801 et seq.) if the products have no significant potential for abuse. The authority to exempt these products was delegated from the Attorney General to the Administrator of the Drug Enforcement Administration (DEA) (28 CFR 0.100(b)), who in turn, redelegated this authority to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration (28 CFR Part 0, Appendix to Subpart R, Section 7(g)). The procedure for implementing this section of the ASCA is found in 21 CFR 1308.33. Three applications which were in conformance with 21 CFR 1308.33 were received and forwarded to the Secretary of Health and Human Services for evaluation. The purpose of this rule is to finalize an interim rule regarding six products which the Deputy Assistant Administrator, Office of Diversion Control, finds meet the exempt anabolic steroid product criteria.
Anabolic Steroid Products Being Added to the List of Products Exempted From Application of the CSA
DEA received three letters dated June 8, 2005, July 1, 2005 and August 22, 2005, written to the DEA on behalf of Interpharm Inc., Lannett Company Inc., and ANDAPharm, LLC., respectively. Each of these three letters contained an application to exempt from control under the CSA two products, each containing esterified estrogens and methyltestosterone. In two letters dated November 14, 2005, DEA provided a copy of the Lannett and ANDAPharm applications to the Department of Health and Human Services (HHS) along with a request for evaluation and a recommendation. In a letter dated November 15, 2005, DEA provided a copy of the Interpharm application to HHS along with a request for evaluation and recommendation. In three separate letters dated March 30, 2006, the Assistant Secretary of Health for HHS recommended that all six products, two products of esterified estrogen and methyltestosterone from each of three applications, be exempted from control under the CSA based on their similarity to the products, Estratest®, Estratest® H.S., EssianTM and EssianTM H.S., which have been exempted from control under the CSA (71 FR 10835, March 3, 2006 and 71 FR 61876, October 20, 2006).
DEA agreed with HHS regarding the similarity of these products to products which have already been exempted from the regulatory controls of the CSA. Further, after reviewing several law enforcement databases, DEA did not find evidence of significant abuse or trafficking of these types of products. Therefore, DEA published an Interim rule with request for comments (71 FR 51996, September 1, 2006) exempting these products from regulatory control under the CSA.
DEA received one comment in opposition to the Interim Rule. As a basis for this objection, the commenter cited generally to Article I, Section 1 of the U.S. Constitution: “All legislative powers herein granted shall be vested in a Congress of the United States, which shall consist of a Senate and House of Representatives.” DEA has considered the comment and determined that the objection is without legal basis.
Thus, the rule is being finalized without change. Accordingly, the Deputy Assistant Administrator, Office of Diversion Control, hereby affirms his order that the following anabolic steroid products be added to the list of products excluded from application of certain controls of the Controlled Substances Act and referenced in 21 CFR 1308.34.
Exempt Anabolic Steroid Products:
|Esterified Estrogens and Methyltestosterone, USP (1.25 mg/2.5 mg)||Interpharm, Inc||Tablets||Esterified Estrogens Methyltestosterone||1.25 mg/Tablet. 2.5 mg/Tablet.|
|Esterified Estrogens and Methyltestosterone, USP (0.625 mg/1.25 mg)||Interpharm, Inc||Tablets||Esterified Estrogens Methyltestosterone||0.625 mg/Tablet. 1.25 mg/Tablet.|
|Methyltestosterone and Esterified Estrogens (2.5 mg/1.25 mg)||Lannett Company, Inc||Tablets||Esterified Estrogens Methyltestosterone||1.25 mg/Tablet. 2.5 mg/Tablet.|
|Methyltestosterone and Esterified Estrogens (Half Strength) (1.25 mg/0.625 mg)||Lannett Company, Inc||Tablets||Esterified Estrogens Methyltestosterone||0.625 mg/Tablet. 1.25 mg/Tablet.|
|Esterified Estrogens/Methyltestosterone, (1.25 mg/2.5 mg) Tablet||ANDAPharm, LLC||Tablets||Esterified Estrogens Methyltestosterone||1.25 mg/Tablet. 2.5 mg/Tablet.|
|Esterified Estrogens/Methyltestosterone, (0.625 mg/1.25 mg) Tablet||ANDAPharm, LLC||Tablets||Esterified Estrogens Methyltestosterone||0.625 mg/Tablet. 1.25 mg/Tablet.|
Regulatory Flexibility Act
The granting of exemption status relieves persons who handle the exempted products in the course of legitimate business from the registration, recordkeeping, security, and other requirements imposed by the CSA. Accordingly, the Deputy Assistant Administrator certifies that this action will not have a significant economic impact upon a substantial number of small entities whose interests must be considered under the Regulatory Flexibility Act (5 U.S.C. 601-612).
Executive Order 12866
The Deputy Assistant Administrator further certifies that this rulemaking has been drafted in accordance with the principles in Executive Order 12866. It has been determined that this is not a significant regulatory action. Therefore, this action has not been reviewed by the Office of Management and Budget. This final rule exempts the identified steroid products from the regulatory controls that apply to controlled substances.
This rule meets the applicable standards set forth in sections 3(a) and 3(b)(2) of Executive Order 12988 Civil Justice Reform.
This rule does not preempt or modify any provision of state law; nor does it impose enforcement responsibilities on any state; nor does it diminish the power of any state to enforce its own laws. Accordingly, this rulemaking does not have federalism implications warranting the application of Executive Order 13132.
Unfunded Mandates Reform Act of 1995
This rule will not result in the expenditure by State, local or tribal governments, in the aggregate, or by the private sector, of $120,000,000 or more (adjusted for inflation) in any one year, and will not significantly or uniquely affect small governments. Therefore, no actions were deemed necessary under the provisions of the Unfunded Mandates Reform Act of 1995.
Congressional Review Act
This rule is not a major rule as defined by § 804 of the Small Business Regulatory Enforcement Fairness Act of 1996 (Congressional Review Act). This rule will not result in an annual effect on the economy of $100 million or more, a major increase in costs or prices, or significant adverse effects on competition, employment, investment, productivity, innovation, or on the ability of United States-based companies to compete with foreign-based companies in domestic and export markets.
21 CFR Part 1308—Schedules of Controlled Substances
The Interim Rule with Request for Comment amending the list of exempt anabolic steroid products described in 21 CFR 1308.34 published at 71 FR 51996, September 1, 2006 is hereby adopted as a final rule without change.Start Signature
Dated: March 8, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control.
[FR Doc. E8-5173 Filed 3-14-08; 8:45 am]
BILLING CODE 4410-09-P